The consumer products giant reached a $40 billion deal to buy Kenvue, the maker of Tylenol, despite a barrage of unproven claims from President Trump and others that use of the pain reliever during pregnancy can cause autism.
With Acquisition, Kimberly-Clark Bets That Tylenol Can Weather the Storm
Written by
in
Food and Drug Administration, Johnson & Johnson, Kennedy, Robert F Jr, Kenvue Inc, Kimberly-Clark Corporation, Labeling and Labels (Product), Mergers, Acquisitions and Divestitures, Regulation and Deregulation of Industry, Suits and Litigation (Civil), Trump, Donald J, Tylenol (Drug), United States Politics and Government